Med-Tech World to host Medical Technology in Small States Conference
Robotic-assisted surgical platform startup Memic have closed a $96 million Series D funding round led by Peregrine Ventures and Ceros, with participation from OurCrowd and Accelmed. On 1 March, the company announced they gained marketing authorisation from the U.S. Food and Drug Administration (FDA) for use in transvaginal benign surgical procedures.
Founded in 2012, the startup headquartered in Tel Aviv has developed a platform, the Hominis, for use in transvaginal benign surgical procedures.
The FDA-approved platform received the greenlight for use in “single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy”. The robot does nonetheless require human intervention to operate, with the surgeon navigating the device from a central console.
Dvir Cohen, co-founder and CEO of Memic, shared:
The Hominis system represents a significant advancement in the growing multi-billion-dollar robotic surgery market. This financing positions us to accelerate our commercialization efforts and bring Hominis to both surgeons and patients in the months ahead,
Eyal Lifschitz, managing general partner of Peregrine Ventures, expressed she hopes such technologies will act as a springboard for additional uses:
Given the broad potential of Hominis combined with a strong management team, we are proud to support Memic and execution of its bold vision,
In addition, the Israel-based company recently raised around $12.5M through OurCrowd, a crowdsourcing platform.
See also: Preveta raises $2m seed funding for AI and data-driven platform prioritising value-based care to improve cancer patient outcomes